Clinical Trial – Compare the Efficacy of a Prophylactic Use of Tenofovir – Burkitt's

Seoul National University Hospital is running a clinical trial to test a drug called Tenofovir to treat Burkitt’s, asubtype of Non-Hodgkin’s Lymphoma. The objective of this study is to analyze factors affecting Hepatitis B Virus (HBV) reactivation in anti-HBc positive patients with Non-Hodgkin’s lymphoma treated with rituximab and compare HBV reactivation rates by duration of prophylactic treatment with tenofovir to contribute to the establishment of an effective prevention strategy.

The drug is Tenofovir.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin’s Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy
Actual Study Start Date : November 2015
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : September 2018

For enrollment please visit


* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.